ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or
“IPA” or the “Company”), a leader in AI-driven biotherapeutic
research and technology, is pleased to announce important Board of
Director changes and upcoming financial reporting activities.
New Board Chairman
Mitch Levine joined the Board of Directors of IPA at IPA’s
recent Annual General Meeting and has been appointed as Chairman of
the Board, bringing a wealth of experience from the life sciences
industry and financial strategy, particularly in Nasdaq market
operations. As CEO and Chairman of SmartHealth Dx since 2022,
Levine has focused the company’s strategy, operational efficiency,
and boosted corporate value. At Oncocyte, he drove significant
growth as CFO from 2017 to 2022, overseeing all financial
operations of the company, managing capital raises, navigating
Nasdaq complexities, and leading major acquisitions and a key
licensing deal in China. His capital markets expertise was widely
recognized as Founder and Managing Member of Enable Capital
Management, LLC, where for 17 years they provided growth capital to
small- and mid-sized public companies, many traded on Nasdaq. His
background also includes a foundational role at The Shemano Group,
a San Francisco-based investment bank focused on technology and
life sciences sectors.
Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies, lauds
Levine’s combination of life sciences and financial acumen as
invaluable for IPA. His guidance is expected to be crucial for
IPA's innovative growth, particularly in antibody discovery and
development, and to further establish IPA as a leader in the
biotech industry. “We anticipate his guidance in financial
strategies and market dynamics to be a significant asset in driving
IPA's innovative growth and expansion, especially as we progress
our cutting-edge biotechnologies like HYFT® and LENSai™.”
Remuneration and Nomination Committee Chairman
Chris Buyse is currently the Chairman of the Remuneration and
Nomination Committee, effective October 2, 2023. Mr. Buyse brings
both experience with Nasdaq traded life science companies as well
as pharmaceutical industry experience. He is currently a Board
member and Chairman of the Audit Committee of Inventiva SA, a
dual-listed company on Euronext Paris and Nasdaq, and a board
member and member of the Audit Committee of Hyloris
Pharmaceuticals, a company listed on Euronext Brussels.
New Audit Committee Chairman
Additionally, IPA is pleased to announce the appointment of Dirk
Witters as the new Chairman of the Audit Committee, effective
November 15, 2023. Mr. Witters brings a strong background in
finance and auditing, having previously served as executive partner
in a corporate finance boutique and was advisor to the founder of
New Rhein Healthcare Investors, a private equity investment firm
focused on healthcare therapeutics and medical devices, where he
assisted with the capital raise of the second investment fund. Mr.
Witters also spent 20+ years with KBC Group’s Corporate and
Investment Banking division where he gained experience in business
development, strategy execution, advisory and corporate finance.
The appointment of Mr. Witters as Chairman of IPA’s Audit Committee
underscores IPA's commitment to maintaining the highest standards
of financial oversight and corporate governance.
"We at IPA are thrilled to embark on this exciting new chapter
with the support of our shareholders and stakeholders, guided by
our esteemed leadership team. The appointment of Mitch Levine as
our Chairman, along with Chris Buyse as Chairman of the
Remuneration and Nomination Committee, and Dirk Witters as the new
Chairman of the Audit Committee, marks a significant milestone for
our company, stated Dr. Bath.” Their combined expertise in the life
sciences sector, financial strategy, and corporate governance,
especially in Nasdaq-listed environments, not only reflects the
strong backing we have from our shareholders but also reinforces
our commitment to excellence and innovation in biotechnology. We
believe that their leadership and insights will be instrumental in
steering IPA towards groundbreaking advancements and sustained
growth in the industry."
Upcoming Second Quarter 2023 Earnings Release Call
IPA will host a conference call to discuss its quarterly results
and recent business highlights for second quarter fiscal year 2024,
on Thursday, December 14, 2023, at 10:30 am Eastern Time. The
financial results will be issued in a press release prior to the
call. Investors, analysts, and other stakeholders are invited to
participate in the conference call, during which IPA's senior
leadership will discuss the financial results and provide insights
into the company's performance and future outlook.
Title: IPA Reports Financial Results and Recent Business
Highlights for Second Quarter Fiscal Year 2024 Event Date: December
14, 2023 Event Time: 10:30 ET Webcast URL:
https://events.q4inc.com/attendee/905281713
Participant Details Participant Toll-Free Dial-In Number: 1
(888) 550-5658 Participant Toll Dial-In Number: 1 (646) 960-0289
Conference ID: 9236374
About ImmunoPrecise Antibodies Ltd
ImmunoPrecise Antibodies Ltd. has several subsidiaries in North
America and Europe including entities such as Talem Therapeutics
LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd., and
ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA
Family”). The IPA Family is a biotherapeutic research and
technology group that leverages systems biology, multi-omics
modeling, and complex artificial intelligence systems to support
its proprietary technologies in bioplatform-based antibody
discovery. Services include highly specialized, full-continuum
therapeutic biologics discovery, development, and out-licensing to
support its business partners in their quest to discover and
develop novel biologics against the most challenging targets. For
further information, visit www.ipatherapeutics.com.
Forward Looking Information
This news release contains forward-looking statements within the
meaning of applicable United States securities laws and Canadian
securities laws. Forward-looking statements are often identified by
the use of words such as “potential”, “plans”, “expects” or “does
not expect”, “is expected”, “estimates”, “intends”, “anticipates”
or “does not anticipate”, or “believes”, or variations of such
words and phrases or state that certain actions, events or results
“may”, “could”, “would”, “might” or “will” be taken, occur or be
achieved. Forward-looking information contained in this news
release includes, but is not limited to, statements relating to the
future expectations for IPA, including expectations regarding IPA
achieving groundbreaking advancements and sustained growth in the
industry. In respect of the forward-looking information contained
herein, IPA has provided such statements and information in
reliance on certain assumptions that management believed to be
reasonable at the time.
Forward-looking information involves known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements stated herein to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking information. Actual
results could differ materially from those currently anticipated
due to a number of factors and risks, as discussed in the Company’s
Annual Information Form dated July 10, 2023 (which may be viewed on
the Company’s profile at www.sedar.com), and the Company’s Form
40-F, dated July 10, 2023 (which may be viewed on the Company’s
profile at www.sec.gov). Should one or more of these risks or
uncertainties materialize, or should assumptions underlying the
forward-looking statements prove incorrect, actual results,
performance, or achievements may vary materially from those
expressed or implied by the forward-looking statements contained in
this news release. Accordingly, readers should not place undue
reliance on forward-looking information contained in this news
release. The forward-looking statements contained in this news
release are made as of the date of this release and, accordingly,
are subject to change after such date. The Company does not assume
any obligation to update or revise any forward-looking statements,
whether written or oral, that may be made from time to time by us
or on our behalf, except as required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231127562186/en/
Investor contact: investors@ipatherapeutics.com
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
Von Mai 2023 bis Mai 2024